A comprehensive review highlights how TP53 mutations contribute to oral cancer development, treatment resistance, and poor patient outcomes. The study summarizes emerging therapeutic approaches, including mutant p53 reactivation, synthetic lethality, and immunotherapy-based strategies, providing new perspectives for precision medicine in oral cancer.A comprehensive review highlights how TP53 mutations contribute to oral cancer development, treatment resistance, and poor patient outcomes. The study summarizes emerging therapeutic approaches, including mutant p53 reactivation, synthetic lethality, and immunotherapy-based strategies, providing new perspectives for precision medicine in oral cancer.

Researchers at Oregon State University have potentially found a new way to treat the most aggressive form of brain cancer, glioblastoma, whose two-year survival rate is less than 30%.

Researchers at Sylvester found a sex-specific immune pathway in glioblastoma: GABA drives tumor-protective immune cells in female models, and blocking the signal improved outcomes. Findings in lab and human samples may point to future treatments tailored for women.